Advertisement
Screener

VolitionRx Limited (VNRX) Graph

VNRX Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $398.66K; Research and development $1.80M; Operating expenses $4.55M; Income tax (m).
  • 2026-03-31: Revenue $985.08K; Research and development $2.85M; Operating expenses $6.33M; Income tax (m).
  • 2025-12-31: Revenue $447.03K*; Research and development $2.47M*; Operating expenses $5.27M*; Income tax (m).
  • 2025-09-30: Revenue $627.28K; Research and development $2.29M; Operating expenses $5.73M; Income tax (m).

Revenue flow

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

VNRX revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Revenue$398.66KOperating expenses$4.55MOperating income-$4.16MOther income, net-$3.16MResearch & development$1.80M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$398.66K$1.80M$4.55M(m)-$7.33M
2026-03-31$985.08K$2.85M$6.33M(m)-$6.66M
2025-12-31$447.03K*$2.47M*$5.27M*(m)-$6.27M*
2025-09-30$627.28K$2.29M$5.73M(m)-$5.38M
2025-06-30$406.69K$2.72M$6.70M(m)-$6.28M
2025-03-31$246.38K$2.61M$5.77M(m)-$5.42M
2024-09-30$474.52K$3.47M$6.34M(m)-$5.82M
2024-06-30$395.80K$3.72M$7.39M(m)-$6.99M
2024-03-31$171.53K$4.63M$8.56M(m)-$8.37M
2023-09-30$165.21K$4.65M$8.82M(m)-$8.45M
2023-06-30$216.31K$5.45M$9.77M(m)-$9.55M
2023-03-31$149.81K$4.91M$9.19M(m)-$8.87M
2022-09-30$32.71K$4.00M$8.03M(m)-$7.81M
2022-06-30$39.75K$3.28M$8.14M(m)-$7.73M
2022-03-31$114.21K$3.59M$7.79M(m)-$7.72M
2021-09-30$25.48K$3.61M$7.59M(m)-$7.18M
2021-06-30$24.78K$2.94M$5.93M(m)-$5.57M
2021-03-31$25.53K$3.87M$6.11M(m)-$6.13M
2020-09-30$575.00$3.18M$4.50M$0.00-$4.34M
2020-06-30$5.19K$3.49M$5.22M$0.00-$5.04M
2020-03-31$544.00$3.89M$5.87M(m)-$5.86M
2019-09-30$17.10K$2.64M$4.19M$0.00-$4.18M
2019-06-30$0.00$2.48M$4.15M$0.00-$4.16M
2019-03-31(m)$2.47M$3.99M(m)-$4.20M
2018-09-30(m)$2.74M$4.45M(m)-$4.48M
2018-06-30(m)$2.69M$4.57M(m)-$4.59M
2018-03-31(m)$2.42M$4.63M(m)-$4.65M
2017-09-30(m)$2.13M$3.88M(m)-$3.89M
2017-06-30(m)$1.81M$3.44M(m)-$3.46M
2017-03-31(m)$1.67M$3.34M(m)-$3.35M
2016-09-30(m)$1.97M$3.48M(m)-$3.48M
2016-06-30(m)$1.75M$2.98M(m)-$2.95M
2016-03-31(m)$1.46M$2.49M(m)-$2.49M
2015-09-30(m)$1.86M$2.97M$4.60K-$2.96M
2015-06-30(m)$1.36M$2.02M(m)-$1.87M
2015-03-31(m)$1.21M$2.35M(m)-$2.01M
2014-09-30$14.79K$1.07M$1.78M(m)-$5.89M
2014-06-30(m)$791.29K$1.05M(m)$816.80K
2014-03-31(m)$870.46K$1.24M(m)-$2.19M
2013-09-30(m)$524.53K$925.57K(m)-$925.57K
2013-06-30(m)$640.64K$1.05M(m)-$1.05M
2013-03-31(m)$593.20K$907.80K(m)-$907.80K
2012-09-30$27.59K$633.80K$900.11K(m)(m)
2012-06-30$11.71K$559.43K$943.17K(m)-$931.47K
2012-03-31$15.67K$511.05K$817.41K(m)-$801.74K
2011-09-30$0.00$292.20K(m)(m)(m)
2011-06-30$0.00$415.52K$640.15K(m)-$640.15K
2011-03-31$0.00$198.08K$335.17K(m)-$335.17K

Revenue and expense 5 month

Period endRevenueResearch and developmentOperating expensesNet income
2010-12-31$0.00$172.19K$894.12K-$894.12K

Revenue and expense 6 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$1.38M$4.65M$10.91M(m)-$13.99M
2025-06-30$653.07K$5.33M$12.47M(m)-$11.71M
2024-06-30$567.33K$8.35M$15.94M(m)-$15.35M
2023-06-30$366.12K$10.36M$18.96M(m)-$18.42M
2022-06-30$153.96K$6.87M$15.93M(m)$15.45M
2021-06-30$50.31K$7.52M$12.04M(m)-$11.70M
2020-06-30$5.74K$7.39M$11.09M$0.00-$10.90M
2019-06-30$0.00$4.95M$8.14M$0.00-$8.36M
2018-06-30(m)$5.11M$9.19M(m)-$9.24M
2017-06-30(m)$3.48M$6.78M(m)-$6.81M
2016-06-30(m)$3.21M$5.47M(m)-$5.44M
2015-06-30(m)$2.57M$4.37M(m)-$3.88M
2014-06-30(m)$1.66M$2.29M(m)-$1.38M
2013-06-30(m)$1.23M$1.96M(m)-$1.96M
2012-06-30$27.38K$1.07M$1.76M(m)-$1.73M
2011-06-30$0.00$617.72K$975.32K(m)-$975.32K

Revenue and expense 9 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-09-30$1.28M$7.61M$18.20M(m)-$17.09M
2024-09-30$1.04M$11.82M$22.29M(m)-$21.17M
2023-09-30$531.33K$15.01M$27.78M(m)-$26.88M
2022-09-30$186.68K$11.20M$23.96M(m)-$23.26M
2021-09-30$75.80K$9.72M$19.62M(m)-$18.88M
2020-09-30$6.31K$10.57M$15.60M$1.00-$15.24M
2019-09-30$17.10K$7.60M$12.34M$0.00-$12.54M
2018-09-30(m)$7.85M$13.64M(m)-$13.72M
2017-09-30(m)$5.62M$10.66M(m)-$10.71M
2016-09-30(m)$5.18M$8.95M(m)-$8.92M
2015-09-30(m)$4.43M$7.33M$4.60K-$6.84M
2014-09-30$14.79K$2.73M$4.07M(m)-$7.27M
2013-09-30(m)$1.76M$2.88M(m)-$2.88M
2012-09-30$54.97K$1.70M$2.66M(m)-$2.61M
2011-09-30$0.00$909.93K(m)(m)-$1.69M

Revenue and expense 12 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31$1.73M$10.08M$23.47M(m)-$23.36M
2024-12-31$1.23M$14.41M$28.26M(m)-$26.97M
2023-12-31$775.30K$19.55M$36.76M(m)-$35.68M
2022-12-31$306.39K$15.33M$32.09M(m)-$30.60M
2021-12-31$90.03K$13.02M$28.42M(m)-$26.99M
2020-12-31$13.43K$14.53M$21.26M(m)-$20.40M
2019-12-31$17.10K$10.36M$16.06M(m)-$16.10M
2018-12-31(m)$10.91M$17.90M(m)-$18.01M
2017-12-31(m)$8.03M$14.70M(m)-$14.77M
2016-12-31(m)$7.90M$12.43M(m)-$11.91M
2015-12-31(m)$6.10M$10.01M-$4.60K-$9.53M
2014-12-31$14.79K$4.04M$5.95M(m)-$8.21M
2013-12-31(m)$2.50M$4.58M(m)-$3.71M
2012-12-31$54.97K$2.77M$4.14M(m)-$4.08M
2011-12-31$0.00$1.52M$2.61M(m)-$2.61M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cardio Diagnostics Holdings, Inc. (CDIO)United States$0.006B
Q/C TECHNOLOGIES, INC. (QCLS)United States$0.008B-1.93
BIOMERICA INC (BMRA)United States$0.011B
IMMUCELL CORP /DE/ (ICCC)United States$0.091B116.10
Insight Molecular Diagnostics Inc. (IMDX)United States$0.129B-3.90
MYRIAD GENETICS INC (MYGN)United States$0.397B-4.84
Alpha Teknova, Inc. (TKNO)United States$0.500B-18.12
QuidelOrtho Corp (QDEL)United States$0.733B-0.90
ACHIEVE LIFE SCIENCES, INC. (ACHV)United States$0.806B-5.88
Intellia Therapeutics, Inc. (NTLA)United States$1.705B-5.92